SCHEMBL2452974

SCHEMBL2452974

CN1c2ccccc2C(C(=O)O)c2c(OCc3c(F)ccc(F)c3F)cccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GUCY1B2 O75343 7/20 0.42
GUCY1A2 P33402 7/20 0.42
GUCY1A1 Q02108 7/20 0.42
GUCY1B1 Q02153 7/20 0.42
HDAC4 P56524 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM1A O60341 2/20 0.35
EGFR P00533 2/20 0.35
SRC P12931 1/20 0.35
ALDH1A1 P00352 1/20 0.35
S1PR5 Q9H228 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
PTGER1 P34995 1/20 0.33
HTR1A P08908 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7797048 0.75 HDAC4 (0.39) HDAC4HDAC7HDAC5MEN1MAPT
SCHEMBL7796571 0.73 HDAC4 (0.46) HDAC4HDAC7HDAC5MEN1MAPT
SCHEMBL8741715 0.72 HDAC4 (0.47) HDAC4HDAC7HDAC5MEN1MAPT
SCHEMBL27488661 0.72 HDAC4 (0.40) HDAC4HDAC7HDAC5MEN1MAPT
SCHEMBL31613807 0.71 HDAC4 (0.66) HDAC4HDAC7HDAC5MEN1MAPT
SCHEMBL2989515 0.71 HDAC4 (0.66) HDAC4HDAC7HDAC5MEN1MAPT
SCHEMBL2218310 0.70 HDAC4 (0.50) HDAC4HDAC7HDAC5MEN1MAPT
SCHEMBL3855305 0.70 HDAC4 (0.42) HDAC4HDAC7HDAC5MEN1MAPT
SCHEMBL27864842 0.70 MEN1 (0.42) HDAC4HDAC7HDAC5MEN1MAPT
SCHEMBL4195312 0.70 HDAC4 (0.37) HDAC4HDAC7HDAC5MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170210825-A1 MONOSPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD OF USE BAYER IP GMBH (US) 2017-07-27 US disclosed
US-9624309-B2 Monospecific and multispecific antibodies and method of use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2017-04-18 US disclosed
EP-2532676-B1 Protease-regulated antibody Bayer Pharma AG (DE) 2017-03-22 EP disclosed
EP-1963372-B1 ANTI-MN ANTIBODIES AND METHODS OF USING THE SAME BAYER HEALTHCARE LLC (US) 2013-07-03 EP disclosed
EP-2532676-A1 Protease-regulated antibody Bayer Pharma Aktiengesellschaft (DE) 2012-12-12 EP disclosed
US-20120301468-A1 ANTI-MN ANTIBODIES AND METHODS OF USING SAME BAYER HEALTHCARE LLC (US) 2012-11-29 US disclosed
EP-2476706-A2 Anti-MN antibodies and methods of using same Bayer HealthCare LLC (US) 2012-07-18 EP disclosed
US-8168758-B2 Anti-MN antibodies and methods of using same BAYER HEALTHCARE LLC (US) 2012-05-01 US disclosed
US-20110229476-A1 MONOSPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD OF USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-09-22 US disclosed
EP-1913391-B1 QUANTITATIVE ASSAYS FOR PDGFR-beta IN BODY FLUIDS SIEMENS HEALTHCARE DIAGNOSTICS (US) 2010-12-29 EP disclosed
WO-2009021754-A2 MONOSPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD OF USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-19 WO disclosed
US-20080311604-A1 Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy BAYER HEALTHCARE LLC 2008-12-18 US disclosed
US-20080311601-A1 Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy BAYER HEALTHCARE LLC 2008-12-18 US disclosed
EP-1946116-A2 METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY Bayer Healthcare, LLC (US) 2008-07-23 EP disclosed
EP-1946115-A2 METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY Bayer Healthcare, LLC (US) 2008-07-23 EP disclosed
EP-1943521-A2 METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY Bayer HealthCare LLC (US) 2008-07-16 EP disclosed
WO-2007056012-A2 METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY BAYER HEALTHCARE LLC (US) 2007-05-18 WO disclosed
WO-2007056011-A2 METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY BAYER HEALTHCARE LLC (US) 2007-05-18 WO disclosed
WO-2007047955-A2 METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY BAYER HEALTHCARE LLC (US) 2007-04-26 WO disclosed
US-20070037224-A1 Quantitative assays for PDGFR-beta in body fluids HAMER PETER J 2007-02-15 US disclosed